CASI Pharmaceuticals Inc (CASI)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

9620 MEDICAL CENTER DR ROCKVILLE, MD 20850

Entremed develops oncology and anti-inflammatory drugs that target disease cells directly and the blood vessels that nourish them. Panzem (2-methoxyestradiol or 2ME2), EntreMed's lead drug candidate, was in clinical trials for cancer in March 2005, and in preclinical development for other indications.

Data as of 2020-08-01
Market Cap239.212 Million Shares Outstanding123.944 Million Avg 30-day Volume490.586 Thousand
P/E Ratio Dividend Yield EPS-0.48
Price/Sales30.963 Price cash flow ratio Price free cash flow ratio-11.4
Book Value0.57 Price to Tangible Book3.58 Alpha0.02
Short Interest Ratio % Short Interest to Float R-squared0.030414
BETA0.918667 52-week High/Low3.82 / 1.15 Stddev0.22664

Are you looking for this stock instead?

View SEC Filings from CASI instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 60 11 (0.72%)
Aggregate 13F shares on 03/31/2020: 13.769 Million 3.673 Million
Aggregate 13F shares on 12/31/2019: 20.44 Million 3.242 Million
Percent change: -32.64% 13.30%
Funds creating new positions: 11 3
Funds Adding to an existing position: 22 6
Funds closing out their position: 5
Funds reducing their position: 15 1
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CASI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CASI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

4.2 Million total shares from 3 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HE WEI-WU CHAIRMAN AND CEO

  • Officer
  • Director
  • 10% Owner
12,809,942 2020-07-22 9

ZHANG LARRY PRESIDENT

  • Officer
20,153 2020-07-22 2

HUANG JAMES

  • Director
0 2020-07-20 1

SALISBURY FRANKLIN CARY JR

  • Director
0 2020-06-16 1

SHROTRIYA RAJESH C MD

  • Director
0 2020-06-16 1

ZHOU QUAN

  • Director
0 2020-06-16 1

WU YUE ALEXANDER

  • Director
0 2020-06-16 1

TARNOW MICHAEL M

  • Director
69,713 2020-06-09 0

BURNS JAMES S

  • Director
473,461 2020-06-05 0

WEALTH STRATEGY HOLDING LTD

  • 10% Owner
9,087,888 2019-12-30 1

ZUKIWSKI ALEXANDER A CHIEF MEDICAL OFFICER

  • Officer
0 2019-12-15 1

REN KEN KEYONG

  • Director
0 2019-06-20 0

SPECTRUM PHARMACEUTICALS INC

SPECTRUM PHARMACEUTICALS CAYMAN, L.P.

  • 10% Owner
10,047,675 2019-04-02 0

HU CYNTHIA W. COO, GEN COUNSEL & SECRETARY

  • Officer
0 2019-01-29 0

SPARKLE BYTE LTD

SNOW MOON LTD

TIANJIN JINGRAN MANAGEMENT CENTER (LIMITED PARTNERSHIP)

HE XIE AI QI INVESTMENT MANAGEMENT (BEIJING) CO., LTD.

LI JIANGUANG

LIN DONGLIANG

YANG FEI

SHONG HUGO

  • 10% Owner
10,198,518 2018-11-13 0

CHI GEORGE CHIEF FINANCIAL OFFICER

  • Officer
0 2018-09-28 0

LI DAPENG

  • 10% Owner
7,756,801 2018-09-11 0

CAPITELLI SARA B VP FIN & PRINCIPAL ACCOUNT OFF

  • Officer
0 2018-07-12 0

WU ALEX

  • Director
0 2018-06-29 0

IDG-ACCEL CHINA GROWTH FUND III L.P.

IDG-ACCEL CHINA III INVESTORS L.P.

IDG-ACCEL CHINA GROWTH FUND III ASSOCIATES L.P.

IDG-ACCEL CHINA GROWTH FUND GP III ASSOCIATES LTD.

HO CHI SING

ZHOU QUAN

  • Director
  • 10% Owner
9,773,370 2018-03-21 0

REN KEN CHIEF FINANCIAL OFFICER

  • Officer
1,080,000 2017-01-05 0

SPARKLE BYTE LTD

SNOW MOON LTD

TIANJIN JINGRAN MANAGEMENT CENTER (LIMITED PARTNERSHIP)

HE XIE AI QI INVESTMENT MANAGEMENT (BEIJING) CO., LTD.

LI JIANGUANG

LIN DONGLIANG

YANG FEI

ZHANG SUYANG

SHONG HUGO

  • 10% Owner
8,498,765 2016-06-24 0

MAK TAK W.

  • Director
0 2016-03-02 0

SAGLIO DANE R CHIEF FINANCIAL OFFICER

  • Officer
0 2014-04-16 0

BUSH DWIGHT L

  • Director
0 2013-05-30 0

HUNTER CEVERA JENNIE

  • Director
0 2013-05-30 0

KNIGHT PETER S

0 2012-12-11 0

RANDALL MARK C M

  • Director
0 2012-03-12 0

BROOKS DONALD S

  • Director
0 2012-01-23 0

SIDOR CAROLYN F V.P. AND CHIEF MEDICAL OFFICER

  • Officer
0 2011-01-05 0

BRAY MARK R VICE PRESIDENT, RESEARCH

  • Officer
0 2011-01-05 0

WEHMEIR-DAVIS KATHY PRINCIPAL ACCOUNTING OFFICER

  • Officer
0 2009-01-27 0

BLISS THOMAS H JR SVP, BUS. & CORP. DEVELOPMENT

  • Officer
0 2008-06-18 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

HE WEI-WU - Director - Officer - > 10% Owner CHAIRMAN AND CEO

2020-07-22 P 2,952,426 $1.90 a 4,836,523 12,809,942.00 direct

ZHANG LARRY - Officer PRESIDENT

2020-07-22 P 20,153 $1.90 a 20,153 20,153.00 direct

HE WEI-WU - Director - Officer - > 10% Owner CHAIRMAN AND CEO see footnote

2020-07-22 P 1,200,000 $1.90 a 7,532,347 12,809,942.00 indirect

SHROTRIYA RAJESH C MD - Director

2020-06-16 A 61,257 a 61,257 0.00 direct

HUANG JAMES - Director

2020-06-16 A 70,400 a 70,400 0.00 direct

SALISBURY FRANKLIN CARY JR - Director

2020-06-16 A 68,800 a 68,800 0.00 direct

ZHOU QUAN - Director

2020-06-16 A 67,429 a 67,429 0.00 direct

WU YUE ALEXANDER - Director

2020-06-16 A 68,800 a 68,800 0.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments